Some 80,000 people may miss out on new psoriasis drug
Adults with the chronic skin disease psoriasis could be set to miss out on a new blockbuster drug to treat the disease.
Around 79,000 people in Ireland have the skin condition, which is also suffered by reality TV star Kim Kardashian.
In April, drug giant Novartis submitted a dossier of clinical, safety and economic evidence to the National Centre for Pharmaeconomics (NCPE) in support of making Cosentyx available through the Health Service Executive (HSE).
However, after evaluating the business case for the drug, the NCPE has recommended to the HSE that the drug not be made available for the price submitted by Novartis.
This is in contrast to the NCPE's counterparts in the UK, the National Institute for Health and Care Excellence, which has recommended to the NHS that it be used as a treatment for adults with severe plaque psoriasis.
Novartis submitted its plan under the HSE high-tech drug scheme and the price of Cosentyx was pitched at €17,030 to €19,487 per patient per year.
However, at the price submitted, the NCPE said it could not recommend the treatment of patients with moderate to severe psoriasis.
A spokesman for the HSE said yesterday: "The NCPE identified significant issues in the Novartis dossier.
"The HSE is considering the NCPE report and will be meeting with Novartis in the near future to discuss the issues identified in the report."
The NCPE are a team of clinicians, pharmacists, pharmacologists and statisticians who evaluate the benefit and costs of medical products.